Insmed (INSM) Competitors

$117.99 +1.99 (+1.72%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$119.40 +1.41 (+1.20%)

As of 04:01 AM Eastern

INSM vs. SNY, GSK, TAK, ARGX, and TEVA

Should you buy Insmed stock or one of its competitors? MarketBeat compares Insmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insmed include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does Insmed compare to Sanofi?

Sanofi (NASDAQ:SNY) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Sanofi has a net margin of 16.95% compared to Insmed's net margin of -144.44%. Sanofi's return on equity of 13.39% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Insmed	-144.44%	-130.11%	-51.57%

Sanofi presently has a consensus price target of $51.00, suggesting a potential upside of 20.23%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 78.79%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

14.0% of Sanofi shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sanofi has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Insmed has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Sanofi has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.10	$8.84B	$3.58	11.85
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 39 more articles in the media than Sanofi. MarketBeat recorded 45 mentions for Insmed and 6 mentions for Sanofi. Sanofi's average media sentiment score of 0.66 beat Insmed's score of 0.53 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	16 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Sanofi beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to GSK?

GSK (NYSE:GSK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

15.7% of GSK shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GSK presently has a consensus price target of $53.00, suggesting a potential upside of 4.03%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 78.79%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

GSK has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.40	$7.54B	$3.85	13.23
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 37 more articles in the media than GSK. MarketBeat recorded 45 mentions for Insmed and 8 mentions for GSK. Insmed's average media sentiment score of 0.53 beat GSK's score of 0.18 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	16 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

GSK has a net margin of 17.82% compared to Insmed's net margin of -144.44%. GSK's return on equity of 44.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Insmed	-144.44%	-130.11%	-51.57%

GSK has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Summary

GSK beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Takeda Pharmaceutical?

Insmed (NASDAQ:INSM) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Insmed currently has a consensus price target of $210.95, suggesting a potential upside of 78.79%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Insmed has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

In the previous week, Insmed had 39 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 45 mentions for Insmed and 6 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 0.53 beat Takeda Pharmaceutical's score of -0.21 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	16 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 2.58% compared to Insmed's net margin of -144.44%. Takeda Pharmaceutical's return on equity of 10.60% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Takeda Pharmaceutical	2.58%	10.60%	5.21%

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A
Takeda Pharmaceutical	$30.09B	1.76	$712.33M	$0.24	69.27

Summary

Insmed beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to argenex?

Insmed (NASDAQ:INSM) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Insmed has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

60.3% of argenex shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 33.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
argenex	31.31%	33.28%	28.16%

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A
argenex	$4.25B	11.75	$1.29B	$22.46	35.74

In the previous week, Insmed had 17 more articles in the media than argenex. MarketBeat recorded 45 mentions for Insmed and 28 mentions for argenex. argenex's average media sentiment score of 0.72 beat Insmed's score of 0.53 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	16 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
argenex	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed currently has a consensus price target of $210.95, suggesting a potential upside of 78.79%. argenex has a consensus price target of $1,017.78, suggesting a potential upside of 26.79%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

argenex beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Teva Pharmaceutical Industries?

Insmed (NASDAQ:INSM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Insmed has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Insmed's net margin of -144.44%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A
Teva Pharmaceutical Industries	$17.26B	2.42	$1.41B	$1.33	27.26

In the previous week, Insmed had 32 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 45 mentions for Insmed and 13 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.67 beat Insmed's score of 0.53 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	16 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed currently has a consensus target price of $210.95, suggesting a potential upside of 78.79%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 15.22%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Teva Pharmaceutical Industries beats Insmed on 9 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$25.14B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.29%	2.79%	5.30%
P/E Ratio	-20.52	18.52	20.99	25.65
Price / Sales	42.17	301.26	555.98	78.93
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	36.30	6.75	9.70	6.66
Net Income	-$1.28B	$24.11M	$3.55B	$333.63M
7 Day Performance	11.99%	-0.53%	-0.56%	-0.11%
1 Month Performance	-23.06%	0.34%	1.17%	3.94%
1 Year Performance	79.84%	78.62%	41.20%	36.07%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.1504 of 5 stars	$117.99 +1.7%	$210.95 +78.8%	+79.6%	$25.14B	$606.42M	N/A	1,664	Trending News Earnings Report Analyst Forecast Analyst Revision High Trading Volume
SNY Sanofi	4.1828 of 5 stars	$43.35 -5.9%	$51.00 +17.6%	-15.1%	$112.39B	$49.35B	10.04	74,846	Analyst Revision
GSK GSK	3.225 of 5 stars	$50.85 -1.5%	$53.00 +4.2%	+40.1%	$104.73B	$43.07B	13.22	66,841	Dividend Cut
TAK Takeda Pharmaceutical	1.0322 of 5 stars	$16.57 -0.3%	N/A	+21.1%	$52.89B	$30.09B	10.39	47,455	News Coverage Gap Down
ARGX argenex	4.6438 of 5 stars	$811.09 +3.5%	$1,016.22 +25.3%	+48.0%	$48.72B	$4.25B	41.55	1,863	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors